Order Article Reprints

Grandal B, Mangiardi-Veltin M, Laas E, Laé M, Meseure D, Bataillon G, El-Alam E, Darrigues L, Dumas E, Daoud E, et al. PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy. Cancers. 2021; 13(4):746. https://doi.org/10.3390/cancers13040746

Grandal, Beatriz, Manon Mangiardi-Veltin, Enora Laas, Marick Laé, Didier Meseure, Guillaume Bataillon, Elsy El-Alam, Lauren Darrigues, Elise Dumas, Eric Daoud, and et al. 2021. "PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy" Cancers 13, no. 4: 746. https://doi.org/10.3390/cancers13040746

Grandal, B., Mangiardi-Veltin, M., Laas, E., Laé, M., Meseure, D., Bataillon, G., El-Alam, E., Darrigues, L., Dumas, E., Daoud, E., Vincent-Salomon, A., Talagrand, L.-S., Pierga, J.-Y., Reyal, F., & Hamy, A.-S. (2021). PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy. Cancers, 13(4), 746. https://doi.org/10.3390/cancers13040746